Search

Meeting abstracts Median survival of advanced malignant pleural mesothelioma (MPM) is less than 2 years, and novel treatments are urgently needed. Immunotherapy with adoptive T cell transfer is an attractive approach that could be added to current therapeutic concepts. Fibroblast activation protein

Bisher konnte nur eine randomisierte, kontrollierte Studie einen positiven Effekt desLungenkarzinom-Screening mittels CT auf die Mortalitat beweisen. Die Reduktion der Mortalitat um 20% in dieser Studie ist allerdings eindrucklich. Die moglichen Vorteile eines Screenings mussen kritisch gegenuber den moglichen Nachteilen (z.B. viele falsch-positive Befunde) abgewogen werden.

The different modalities in the treatment of tuberculosis (TB) changed within the last century. With the beginning of the era of effective antibiotic treatment, indication for surgical methods became rare. The combination of different classes of antibiotics to treat TB is most often effective but several multi-drug-resistant germs were created, leading to the need of surgical resection as adjuvant treatment. The aim of this review is to summarize the current role of surgical therapy in treating TB.

The idea of follow-up visits in lung cancer patients treated in a curative intent is on one side early detection and management of treatment related complications and on the other side a long term surveillance program for early detection of new primary lung cancers or recurrences of the primary lung cancer allowing curative (re)-treatment. The first is best performed by the specialists (thoracic surgeons, oncologists, radiotherapists) and the intervals of the follow-up visits are 3-6 months. In this phase adjuvant therapies as well as a specific surveillance program should be determined. Smoking cessation is strongly recommended and an adequate support should be offered. Patients treated in a curative intent and who are in an adequate performance status should be seen in six months intervals in the first three years and thereafter annually by assessing the medical history, physical exam and for applying imaging modalities such as chest X-ray or CT-Scan of the chest and upper abdomen. The patient should be instructed to detect symptoms and react accordingly. Positron Emission Tomography, sputum cytology, tumor markers and blood tests as well as fluorescence bronchoscopy are not recommended for routine follow-up except in controlled randomized trial protocol. These statements are based on guidelines from several societies as well as from a literature research.